TS-075245 — Problem Although cyclin dependent kinase 9 (CDK9) is a promising drug target, traditional small-molecule inhibitors face challenges due to CDK9's structural similarities with other kinases, leading to off-target effects and limited efficacy Solution Applications Advantages Seeking opp…

TS-075242 — THE PROBLEM Although immune checkpoint blockade (ICB) has emerged as promising cancer immunotherapy, many tumors fail to respond to ICB. This failed response is often driven by the activation of TGF-β1 in the tumor microenvironment (TME), which induces regulatory T cells and inhibits the funct…

TS-075191 — PROBLEM Cancer immunotherapies (e.g. ICB, CAR-T cells, and conventional bispecific T cell engagers) have transformed treatment of hematological and solid malignancies; however, their impact is limited by several factors including insufficient durability of therapeutic activity, tumor heterogeneity,…

TS-075186 — PROBLEM Exhausted CD8 T cells significantly limit the effectiveness of immunotherapies and cell therapies in cancer and chronic viral infections. Persistent antigen exposure drives durable epigenetic reprogramming that locks T cells into a dysfunctional state, silencing effector and memory-associat…

TS-075167 — PROBLEM CAR T-cell therapy against CD19 has become the standard of care for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), the most common kind of lymphoma. Recent studies have identified clinical risk factors for prediction of CAR T therapy failure; however, these risk factors are inconsis…

TS-075163 — THE PROBLEM High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…

TS-075162 — THE PROBLEM Despite advances in classical Hodgkin’s Lymphoma (cHL) treatment, significant challenges persist with up to 40% of patients relapsing after first-line therapy and 50% after autologous stem cell transplant (aSCT). Current therapies like brentuximab vedotin and checkpoint inhibitors…

TS-075158 — Problem The global immune checkpoint inhibitor (ICI) market is ~$60B. However, only ~20% of patients derive long-term survival benefit. The current standard of care biomarker Tumor Mutation Burden (TMB) performs poorly and there is no universal biomarker with robust validated predictive ability. Opportunity A companion diagnostic for identifying patients who benefit with ICI would unlock a large market by improving patient outcome and enabling a pan-cancer treatment indication that helps newer market entrants to better compete with incumbents. Solution Genomic Score that Predicts Survival: We have developed a pan-cancer genomic scoring system encompassing ~170 genes that predicts long term survival with immune checkpoint inhibition (ICI) Derivation: Developed from next-generation sequencing genomic data from 54 Neuroendocrine neoplasms who received ICIs at OSU Validation: Performed by analyzing and scoring 20,563 genomic alterations in 1,662 ICI treated patients with 10 different cancers from a publicly available dataset. (Samstein et al., Nature Genetics 2019). Broad Applicability: NSCLC, Melanoma, Colorectal Cancer, Bladder cancer and Neuroendocrine Neoplasms. Competitive Advantage The genomic score performed better than the TMB score (current standard of care) AUC of 0.87-0.95 for genomic score vs AUC of 0.57 for TMB Predictive of survival in 5 types of cancer including NSCLC Applications Biotech/Pharma companies: Develop a companion diagnostic to facilitate ICI drug development and improve patient outcome that leads to a new pan-cancer treatment indication that competes strongly with established players such as Keytruda and Opdivo which lose patent exclusivity within 3 years Payors/Nationalized Health Systems: Accurately predicting survival benefit helps maximize benefit from expenditure on ICI

TS-075141 — THE PROBLEM Current MS treatments typically employ broad immunosuppression rather than targeting specific pathways, resulting in significant side effects and inadequate responses in many patients. The IL-6/STAT3 pathway is critical for balancing inflammatory T effector cells and protective regulato…

TS-057778 — A novel monoclonal antibody (PIIO-1) targeting the ligand-free form of GARP, the non-signaling docking receptor for TGFβ. PIIO-1 distrupts transforming growth factor-β (TGF-β) signalling in the tumor microenvironment, primarily on T regulatory cells, consequently augmenting anti-tumor immunity and overcoming ICB resistance . Unlike market competitors, ABBV-151 and DS-1055a which bind the TGF-β1/GARP complex, PIIO-1 prevents activation of all 3 TGF-β isoforms, avoiding isoform compensation and avoiding the potential on-target, adverse effects of binding the TGF-β1/GARP complex found on platelets.